Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/27504
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kritsanaviparkporn C. | |
dc.contributor.author | Sangaphunchai P. | |
dc.contributor.author | Treesirichod A. | |
dc.date.accessioned | 2022-12-14T03:17:30Z | - |
dc.date.available | 2022-12-14T03:17:30Z | - |
dc.date.issued | 2022 | |
dc.identifier.issn | 3786323 | |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123124205&doi=10.25259%2fIJDVL_1384_20&partnerID=40&md5=e989027d7191091d680ace8251495180 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/27504 | - |
dc.description.abstract | Background: Topical moisturizer is recommended for atopic dermatitis. Aims: The aim of the study was to investigate the knowledge gap regarding the efficacy of moisturizer in young patients. Methods: A systematic review and meta-analysis were conducted on randomised controlled trials comparing participant’s ≤15 years with atopic dermatitis, receiving either topical moisturizer or no moisturizer treatment. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. Results: Six trials were included (intervention n= 436; control n= 312). Moisturizer use extended time to flare by 13.52 days (95% confidence interval 0.05–26.99, I2 88%). Greater reduction in risk of relapse was observed during the first month of latency (pooled risk ratio 0.47, 95% confidence interval 0.31–0.72, I2 28%) compared to the second and third months (pooled risk ratio 0.65, 95% confidence interval 0.47–0.91, I2 35% and pooled risk ratio 0.63, 95% confidence interval 0.47–0.83, I2 33%, respectively).Treated patients were 2.68 times more likely to experience a three–six months remission (95% confidence interval1.18–6.09, I2 56%). Moisturizer minimally improved disease severity and quality of life. Limitations: There is a dire need to conduct randomised controlled trials with more robust and standardised designs. Conclusion: Moisturizer benefits young patients with atopic dermatitis. However, more research is needed to better estimate its efficacy. © 2022 Indian Journal of Dermatology, Venereology and Leprology - Published by Scientific Scholar | |
dc.language | en | |
dc.subject | antihistaminic agent | |
dc.subject | calcineurin | |
dc.subject | corticosteroid | |
dc.subject | pimecrolimus | |
dc.subject | atopic dermatitis | |
dc.subject | data analysis | |
dc.subject | disease exacerbation | |
dc.subject | disease severity | |
dc.subject | drug efficacy | |
dc.subject | eczema | |
dc.subject | erythema | |
dc.title | Efficacy of moisturizers in paediatric atopic dermatitis: A systematic review and meta-analysis of randomised controlled trials | |
dc.type | Review | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Indian Journal of Dermatology, Venereology and Leprology. Vol 88, No.1 (2022), p.22-31 | |
dc.identifier.doi | 10.25259/IJDVL_1384_20 | |
Appears in Collections: | Scopus 2022 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.